Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. (NASDAQ: INMB) on January 23, 2020, reporting an event that occurred on January 27, 2020. The Company is an emerging growth company incorporated in Nevada.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or total debt. The only specific financial data disclosed relates to a share repurchase transaction:
- Shares Repurchased: 220,000 shares of common stock.
- Purchase Price: $4.60 per share.
- Total Transaction Value: $1,012,000.
Material Changes
The primary material change reported is the reduction of outstanding shares held by Linda F. Powers following the repurchase agreement:
- Prior Ownership: Approximately 10.4% of outstanding common stock.
- Post-Transaction Ownership: Approximately 8.6% of outstanding common stock.
Management Commentary and Outlook
Management, specifically the Board of Directors and Audit Committee, approved the Repurchase Agreement. The Company stated that the purchase price of $4.60 per share is considered "attractive" and that the transaction is expected to be "accretive." No forward-looking guidance, risk factors, or contingencies beyond the terms of this specific agreement were disclosed in this filing.
Investor Verification Checklist
- Verify the exact terms and conditions in the Common Stock Repurchase Agreement (Exhibit 10.1).
- Confirm the current total number of outstanding shares to validate the percentage ownership calculations (10.4% to 8.6%).
- Review the Company's cash position to ensure the $1,012,000 outflow does not impact liquidity for ongoing operations.
- Check subsequent filings for any further share repurchases or changes in insider ownership.